Agentix (AGTX) Research & Development (2013 - 2026)
Agentix's Research & Development was $16,635 in fiscal Q1 2027 (quarter ended Jun 30, 2026), down 83.4% from $100,000 a year earlier.
Powered by 
Analysis
Agentix (AGTX) Research & Development (2013 - 2026) Analysis & Trends
On a trailing twelve-month basis, Agentix's Research & Development was $41,714 through Jun 30, 2026, down 81.5% year-over-year; for FY2026 (ended Mar 31, 2026), it was $125,079, down 30.9% from FY2025.
- Research & Development shows a five-year compound annual growth rate of -19.3% (FY2021 to FY2026).
- In earlier fiscal years, Research & Development was $180,987 in FY2025 (+3.3%), $175,268 in FY2024 (-75.4%), $711,506 in FY2023 (+154.2%) and $279,912 in FY2022.
- The fiscal Q1 2027 figure marks the lowest quarterly Research & Development since fiscal Q2 2025.
- Compared with a year earlier, Research & Development was higher in three of the last five quarters, with growth averaging 25.0%.
- The best year-over-year quarter for Research & Development over five years was fiscal Q1 2024 (growth of 209.5%); the worst was fiscal Q1 2027 (a decline of 83.4%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Agentix | 801,339.00 | 788,533.00 | - | 16,635.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16,635.00 |
| Sep 30, 2025 | 25,079.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 90,349.00 |
| Dec 31, 2024 | 23,287.00 |
| Sep 30, 2024 | 11,850.00 |
| Jun 30, 2024 | 55,501.00 |
| Mar 31, 2024 | 46,024.00 |
| Dec 31, 2023 | -87,304.00 |
| Sep 30, 2023 | 58,366.00 |
| Jun 30, 2023 | 158,182.00 |
| Mar 31, 2023 | 183,830.00 |
| Dec 31, 2022 | 192,032.00 |
| Sep 30, 2022 | 284,532.00 |
| Jun 30, 2022 | 51,112.00 |
| Feb 28, 2022 | 84,050.00 |
| Nov 30, 2021 | 42,950.00 |
| Aug 31, 2021 | 113,912.00 |
| May 31, 2021 | 57,500.00 |
| Feb 28, 2021 | 178,332.00 |
API Access
Agentix Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=AGTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "AGTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=AGTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();